Summary of the third quarter of 2020:
Cash position
Financial Outlook 2020
The company offers updated profit forecasts for 2020. First, the company provided comprehensive profit forecasts for 2020 on February 26, 2020, but subsequently withdrew its forecast on April 6, 2020, due to immediate environmental advances and persistent COVID-related uncertainties. 19.
The company expects overall earnings by 2020 to be between $184. 9 million and $186. 9 million, representing a minimum of 1% to 2% year-over-year overall earnings of $189. 5 million in 2019.
After the adoption of CSA 842, the 2019 earnings included approximately $5. 0 million in lease gains similar to undeniable leases, which will not contribute to the company’s long-term profits. , the profit diversity forecast for 2020 reflects an expansion of profits from approximately 0% to 1% year-on-year on an operational basis.
For those who are unable to participate, a two-week call will be held at 877-660-6853 (201-612-7415 for foreign calls); Password 13711024 The webcast will be archived investisseurs. tactilemedical. com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in the progression and commercialization of home healing devices that treat chronic swelling situations such as lymphedema and chronic venous insufficiency. Tactile Medical’s project is to help others with chronic diseases live better and take care of themselves at home. The exclusive supply includes complex and clinically displayed pneumatic compression devices, as well as continuity of care facilities provided through a national network of product specialists and trainers, reimbursement experts, patient advocates and physicians. This combination of products and facilities ensures that tens of thousands of patients get the home remedy they need annually to better manage their chronic diseases. Tactile Medical is proud that our responses help increase clinical efficiency, reduce overall physical care prices and improve the quality of life of patients with chronic diseases.
Use of non-PCGA monetary measures
This press release includes adjusted EBITDA non-GAAP monetary measures, non-GAAP income adjustments, adjusted gross margin, and adjusted EBITDA margin, which differ from monetary measures calculated in accordance with the accepted accounting principles (“GAAP”) of the United States.
The EBITDA adjusted in this release represents the net source of income or loss, plus interest expense, net or less interest expense, net, less tax profits or more source of income tax, more depreciation and amortization, plus share-based repayment expenses, more impairment and amortization of shares, and more CEO transition costs The EBITDA margin adjusted in this edition represents the net margin (net source of income or losses between total revenue), about the same parts as adjusted EBITDA, but as a percentage of revenue. Reconciliations between the adjusted EBITDA and the net source of income and the adjusted EBITDA margin and net margin are included in this press release.
(1) Only source of rental gain excluded from the source of earnings for the 3 and nine months ended September 30, 2019 in the adjustment similar to rentals initiated before December 31, 2018, who registered on monthly rentals for the 3 and nine months ended September 30, 2019 and did not contribute to the Company’s profit effects in 2020.
(1) Single rental profit source excluded from the 2019 adjustment gain source similar to rentals that took effect before December 31, 2018, which were recorded as one-month rentals in 2019 and do not contribute to the Company’s earnings in The Earnings Diversity Forecast for 2020 reflects an expansion of profits from around 0% to 1% year-on-year on an operational basis.